List view / Grid view
Scientists at Celgene Corporation developed a screening process incorporating the Octet® HTX system to identify pools and clones with higher concentrations of bispecific antibodies. Higher throughput was achieved from the multiple simultaneous measures possible on the Octet system and rapid assay times, such as binding optimisation in only 10 minutes.…
Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.
Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.
In this In-Depth Focus are articles investigating how CROs can help to drive innovation and how CRISPR technologies could be used for drug screening purposes.
Having worked in antibody research for over 20 years, Gary McLean has seen how the industry has progressed and understands the potential that antibodies have in the future of medicine. Nikki Withers hears how the focus has shifted from discovery to genetic sequence manipulation and how this can be applied…
Protein therapeutics are a major class of biopharmaceuticals and monoclonal antibodies (mAbs) rule this domain. In this article, Dr Nancy Lopez-Anton outlines the key technologies employed in this important therapeutic discovery area; how they have evolved and what obstacles must be navigated to ensure future success.
Cell line development typically includes the screening of thousands of clones to identify the few that are stable, grow as expected and produce high yields of the bioproduct.
The articles in this antibodies In-Depth Focus assess the methods used to develop antibody therapeutics and the evolution of this area of medicine to identify drug targets.
This in-depth focus discusses screening and the uses of phenotypic profiling in drug discovery. Also examined is the role that CRISPR/Cas9 gene editing and native mass spectrometry play.
In this Screening In-Depth Focus, scientists from the Assay Development and Screening Platform of Helmholtz Zentrum München provide an overview of different high-throughput screening (HTS)-applicable assay types that can be applied to drug discovery campaigns. Plus an interview with Lee Babiss, CEO of drug discovery firm X-Rx, on the benefits…
